Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation

Who Optimizes SG&A Costs Better?

In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Eli Lilly and Company, a stalwart in the pharmaceutical industry, and Bio-Techne Corporation, a rising star in biotechnology, present an intriguing comparison. Over the past decade, Eli Lilly's SG&A expenses have consistently hovered around $6.4 billion annually, reflecting a stable yet substantial investment in administrative functions. In contrast, Bio-Techne's SG&A costs have shown a dynamic growth, increasing by over 550% from 2014 to 2023. This growth trajectory highlights Bio-Techne's aggressive expansion strategy. However, the data for 2024 is incomplete, leaving room for speculation on future trends. As these companies navigate the complexities of their respective industries, their ability to optimize SG&A expenses will be pivotal in sustaining competitive advantage.